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CLINICAL STUDYThe Impact of an Antireflux Catheter on Target
Volume Particulate Distribution in
Liver-Directed Embolotherapy: A
Pilot Study
Alexander S. Pasciak, PhD, James H. McElmurray, MD,
Austin C. Bourgeois, MD, R. Eric Heidel, PhD, and
Yong C. Bradley, MDABSTRACT
Purpose: To determine if there are differences in hepatic distribution of embolic particles following infusion with a standard
end-hole catheter versus an antireﬂux microcatheter.
Materials and Methods: This prospective study included nine patients (age, 48–86 y) enrolled for treatment of hepatocellular
carcinoma (n ¼ 6), liver-dominant metastatic disease (n ¼ 2), or intrahepatic cholangiocarcinoma (n ¼ 1) with resin yttrium-90
(90Y) microspheres. Before 90Y treatment, each patient received two same-day sequential lobar infusions of technetium 99m
(99mTc) macroaggregated albumin (MAA) via a conventional end-hole catheter and an antireﬂux microcatheter positioned at
the same location. Differences in technetium 99m–MAA distribution within tumor and nontarget sites were evaluated by single-
photon emission computed tomography (SPECT) on a qualitative and semiquantitative basis. The antireﬂux microcatheter was
used for the ensuing 90Y treatment, with posttreatment 90Y positron emission tomography/computed tomography to assess
distribution of 90Y microspheres.
Results: Decreases in hepatic nontarget embolization were found in all patients when the antireﬂux catheter was used. These
decreases ranged from a factor of 0.11 to a factor of 0.76 (mean, 0.42; σ ¼ 0.19), representing a 24%–89% reduction. Increased
tumor deposition was also noted in all patients, ranging from a factor of 1.33 to a factor of 1.90 (mean, 1.68; σ ¼ 0.20),
representing a relative increase of 33%–90%. Both ﬁndings were statistically signiﬁcant (P o .05).
Conclusions: Although this pilot study identiﬁed differences in the downstream distribution of embolic particles when the
antireﬂux catheter was used, further investigation is needed to determine if these ﬁndings are reproducible in a larger patient
cohort and, if so, whether they are associated with any clinical impact.
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spheres has become a widely used treatment for liver-
dominant metastatic cancer and primary hepatocellular
carcinoma (1,2). As with any liver-directed embolotherapy,
the utility of radioembolization rests on the delivery of
sufﬁcient treatment to the tumor to produce a therapeutic
effect while sparing normal liver and extrahepatic tissues
from excessive toxicity. In this context, one potential rare
complication associated with radioembolization is gastro-
intestinal tract ulceration from extrahepatic nontarget
embolization of radiation-sensitive tissues in the stomach
or small intestine (3,4). If pretreatment angiograms indicate
that nontarget embolization may be a risk, occlusion of the
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Volume 26 ’ Number 5 ’ May ’ 2015 661right gastric and gastroduodenal arteries is often performed
before radioembolization (5,6). Although incidence rates of
gastrointestinal ulceration are very low, devices such as
antireﬂux catheters have been introduced to reduce the
likelihood of extrahepatic nontarget embolization by pre-
venting retrograde ﬂow (7–9) of microspheres into unpro-
tected gastroenteric collateral vessels.
Although antireﬂux catheters are commonly marketed
as safety devices, there is preliminary evidence suggesting
that they may also alter the downstream distribution of
therapies such as radioembolization. A recent study (7)
showed increased penetration of tantalum microspheres
distal to the site of infusion in a renal porcine model
when an antireﬂux microcatheter was used. Although this
ﬁnding shows promise, its reproducibility in human
hepatic radioembolization in the setting of variable
tumor neovascularity remain unexplored. In the present
work, nuclear imaging was used to evaluate changes in
microparticle distribution, particularly in distal tumor,
during hepatic radioembolization with the use of an
antireﬂux microcatheter.
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.MATERIALS AND METHODS
Serial Infusion Protocol
The protocol in this prospective trial was approved by the
performing site’s institutional review board. Informed
consent was obtained from all study participants. Enroll-
ment criteria included patients with unresectable liver
cancer clinically referred for hepatic 90Y radioemboliza-
tion for on- and off-label treatment of their disease, with
no sex or race restriction. Exclusion criteria included total
bilirubin level4 2.0 mg/dL, serum albumin levelo 3.0 g/
dL, aspartate and alanine aminotransferase levels no
greater than ﬁve times the normal level, life expectancy
o 12 weeks, or Eastern Cooperative Oncology Group
performance status4 2. Nine patients (age, 48–86 y) were
enrolled for treatment of hepatocellular carcinoma (n ¼
6), liver-dominant metastatic disease (n ¼ 2), or intra-
hepatic cholangiocarcinoma (n ¼ 1). Median Model for
End-stage Liver Disease score was 7 (range, 6–13), with
ﬁve of nine patients classiﬁed as having Child–Pugh class
A cirrhosis and none classiﬁed as having class C cirrhosis.
Segmental tumor-associated portal vein thrombus was
present in one patient, and two patients had received
transarterial chemoembolization greater than 6 months
earlier. Mean tumor diameter was 7.9 cm (range, 3.8–14.6
cm), and the mean percentage tumor involvement in the
treated lobe was 30% (range, 9%–61%). Additional dem-
ographic data are shown in Table 1.
Serial low-particulate infusions of technetium-99m
(99mTc) macroaggregated albumin (MAA) were performed
on the same day, in the same patient, and at the same point
of infusion, with the only difference being the microcatheter
used: a conventional end-hole microcatheter or an anti-
reﬂux microcatheter (Sureﬁre Infusion System; Sureﬁre
Pasciak et al ’ JVIR662 ’ Pilot Study: Antireﬂux Catheter for Liver-Directed EmbolotherapyMedical, Westminster, Colorado). The same interventional
radiologist (J.H.M.) administered all MAA doses to each
patient from a 5 mL syringe (3 mL volume) in small
aliquots using a push-pause infusion technique. One MAA
infusion was performed using a 2.8-F Progreat end-hole
microcatheter positioned at the expected future treatment
location, whereas the other infusion used a 3-F antireﬂux
microcatheter positioned at the same location. Single-
photon emission computed tomography (SPECT) imaging
was performed immediately following each infusion on a
Symbia S SPECT system (Siemens, Bad Neustadt an der
Saale, Germany) with a 128  128  128 matrix size,Figure 1. Flowchart describing the dual-infusion protocol used to coiterative reconstruction, and a body contouring orbit. The
scan time was varied based on the injected activity to obtain
acceptable image quality (Fig 1). The elapsed time between
SPECT imaging of the same-day serial MAA infusions
ranged from 192 to 286 minutes (mean, 238 min).
Because this protocol included same-day serial infu-
sion of 99mTc MAA, residual MAA from the ﬁrst
infusion may have persisted at the time the second
infusion was imaged. To minimize error associated with
persistent activity, a technique commonly used in same-
day renal (10) and cardiac perfusion (11) studies was
applied. The ﬁrst 99mTc MAA infusion had a meanmpare antireﬂux and end-hole microcatheters.
Volume 26 ’ Number 5 ’ May ’ 2015 663activity of 111 MBq (range, 99–128 MBq), whereas the
second had a mean activity of 595 MBq (range, 530–650
MBq). Considering only physical decay of 99mTc from
the ﬁrst to the second infusion, the maximum residual
activity from the ﬁrst infusion was less than 15% of the
activity injected in the second infusion. A 15% residual
activity represents a worst case for the study at the
shortest interprocedural delay used, 192 minutes (Fig 1).
Another potential concern was alteration of vascular
ﬂow into the tumor compartment resulting from residual
embolic particles from the ﬁrst 99mTc MAA infusion at
the time the second infusion was administered. This was
mitigated by use of low-particulate dosages of less than
40,000 particles for infusion 1 and less than 200,000
particles for infusion 2. A nonrandomized 2  2 cross-
over design was used, with the initial ﬁve study patients
receiving the ﬁrst 99mTc MAA infusion with the antire-
ﬂux microcatheter and the second infusion with the end-
hole microcatheter. The catheter order was reversed in
the remaining study subjects.
Treatment Protocol
Each study participant was treated with resin 90Y radio-
embolization via the antireﬂux microcatheter
(Fig 1). Catheter positioning was veriﬁed to be identical
to that used during the 99mTc MAA infusions. The same
push-pause infusion technique used for the MAA infu-
sions was also used for the radioembolization delivery.
Resin microsphere treatment dosage was determined
according to the manufacturer-recommended body sur-
face area treatment planning model (12). Following
treatment, a liver-only 90Y positron emission tomogra-
phy/computed tomography (PET/CT) scan was per-
formed on a Biograph mCT PET/CT scanner (Siemens)
with the following scan parameters: time of ﬂight, point-
spread function resolution recovery, ordered-subset
expectation maximization reconstruction with one iter-
ation and 21 subsets, continuous bed motion at 0.2 mm/s,
and a 400  400 matrix size. A detailed review of 90Y
PET/CT is provided elsewhere (13).
Nuclear Image Analysis
A board-certiﬁed nuclear medicine radiologist (Y.C.B.)
reviewed the SPECT images from both infusions of
MAA, blinded to which catheter was used. Pretreatment
contrast-enhanced hepatic CT, [18F]ﬂuorodeoxyglucose
(FDG) PET/CT, or hepatic-protocol magnetic resonance
(MR) images were used to identify regions of tumor
distal to the catheter position (ie, downstream) in the
treated lobe. This distal region of interest (ROI) place-
ment was selected based on previously reported results
with the use of the antireﬂux catheter (7). One or more
identically placed spherical ROIs with a 2-cm maximum
diameter were drawn on each SPECT scan on an XD3
workstation (Mirada Medical, Denver, Colorado), and
the number of counts contributing to each region wasrecorded and averaged (Fig 2). These data were
normalized by the decay-corrected calibrated activity of
99mTc administered for the infusion, as well as the total
live scan time, so that results from both infusions could
be directly compared in terms of a relative change in
activity deposition in the tumor. As ROIs were drawn in
the same location for each SPECT scan, these regions
were subject to the same attenuation, and this variable
was removed from the ﬁnal answer, eliminating the need
for attenuation-corrected images. Unfortunately, to elim-
inate inﬂuence from attenuation, this technique necessi-
tated the use of a small ROI (o 2 cm) and required a
segmented analysis. This method was based on widely
used semiquantitative regional cardiac SPECT (14), and
has been further vetted with a phantom study described
later. The aforementioned process was repeated in areas
of normal hepatic parenchyma in the treated lobe to
assess changes in MAA deposition in normal liver.
Following treatment of the patient with the antireﬂux
catheter, a board-certiﬁed nuclear medicine radiologist
compared the 90Y PET/CT scan with the 99mTc MAA
SPECT performed following infusion with the antireﬂux
catheter to conﬁrm the validity of MAA as a resin
microsphere surrogate for each case.Phantom Validation
A cylindrical phantom with a diameter of 12 cm and a
volume of 1,750 mL containing a peripheral cylindrical
insert with a diameter of 4.5 cm and a volume of 300 mL
was used to validate the quantiﬁcation methodology
(Fig 3). The phantom background and insert were ﬁlled
four times with 99mTc with total activities mirroring the
low and high MAA activities used in patients at two
different known background and insert relative activity
concentrations, 3.3:1 and 6.2:1. Four SPECT scans of
the phantom were obtained with use of the same scan
time, reconstruction parameters, and postacquisition
analyses that were used in patient scans following the
low-dose and high-dose administrations, respectively.Statistical Analysis
Skewness and kurtosis statistics were used to assess the
assumption of normality of difference scores for the
within-subjects analyses. Paired t tests were used for
comparisons of catheters. An α-value of 0.05 was used to
assume statistical signiﬁcance, and all analyses were
conducted with SPSS software (version 21; IBM,
Armonk, New York).RESULTS
The results of the phantom veriﬁcation of the method-
ology described are presented in Table 2. The maximum
error in assessing the relative change in the known
activity concentration of the phantom insert was 5.6%.
Figure 2. (a) Distribution of 99mTc MAA on axial SPECT following infusion with an end-hole catheter in a 73-year-old man with HCC
(patient 9; Table 1). (b) Axial SPECT demonstrates the distribution of MAA following infusion with an antireﬂux catheter. (c)
Pretreatment axial hepatic-protocol CT demonstrates a right-lobe hepatic mass. Example spherical 2-cm-diameter ROIs were used to
measure changes in distal tumor and normal liver MAA uptake. Quantitative analysis showed changes in MAA deposition by a factor of
1.77 (77% increase) in distal tumor and a factor of 0.40 (60% decrease) in normal liver with the antireﬂux catheter.
Figure 3. Fused SPECT and CT images from the phantom
validation study with a 3.2:1 nominal insert-to-background
activity concentration ratio. Fusion was performed on a Leo-
nardo workstation (Siemens). Segmented phantom analysis
with known activity concentrations resulted in a maximum error
of 5.6% in the semiquantitative model used.
Pasciak et al ’ JVIR664 ’ Pilot Study: Antireﬂux Catheter for Liver-Directed EmbolotherapyThe maximum error in assessing the change in the
phantom background was 3.5%.
Of the nine patients enrolled, eight completed the
study, including radioembolization treatment and post-
treatment 90Y PET/CT imaging. However, as a result of
escalation of liver-function test results between the MAAand treatment components of the study, one patient with
HCC could not be treated. Identical catheter positioning
was conﬁrmed with archived images in all patients when
using the end-hole and antireﬂux microcatheters for
infusion of 99mTc MAA and the subsequent treatment
with radioembolization (Fig 4).
In all nine patients, the 99mTc MAA same-day SPECT
scans qualitatively revealed more uniform and extensive
tumor coverage with greater relative activity deposition
when the antireﬂux catheter was used. Semiquantitative
analysis also revealed increases in MAA uptake in distal
tumor in all nine patients. Consistent results were
obtained regardless of tumor type and independent of
pretreatment imaging obtained on contrast-enhanced
CT, hepatic-protocol MR imaging, or FDG PET/CT
used to reference the true tumor location (Figs 2, 5a–5c,
6a–6c).
Relative to the end-hole catheter, tumor ROI MAA
deposition with the antireﬂux catheter changed by a
factor ranging from 1.33 to 1.90 (mean, 1.68; σ ¼ 0.20),
which represents an increase in tumor deposition ranging
from 33% to 90% when the antireﬂux catheter was used.
This relative increase in deposition with the antireﬂux
catheter was statistically signiﬁcant (P o .05). The
infusion order (end-hole catheter or antireﬂux catheter
ﬁrst), patient demographics, and relative change in
MAA deposition distal to the site of infusion are shown
in Table 1 for each study patient. There was no
signiﬁcant difference in the relative change in tumor
Table 2 . Results from Experimental Phantom Study
Result
Measurement 1 Measurement 2
First Scan, Low
Activity
Second Scan,
High Activity
First Scan, Low
Activity
Second Scan,
High Activity
Injected total activity (MBq) 102.4 587.8 98.2 582.9
Injected relative insert:background activity concentration 3.3:1 6.2:1 6.2:1 3.3:1
Injected* relative change in activity concentration in phantom
insert from ﬁrst to second scan
– 1.45 – 0.69
SPECT† relative change in activity concentration in phantom
insert from ﬁrst to second scan
– 1.38 – 0.71
Percentage error, SPECT vs injected in phantom insert (%) – 5.56 – 3.50
Injected relative change in activity concentration in phantom
background from ﬁrst to second scan
– 0.76 – 1.31
SPECT relative change in activity concentration in phantom
background from ﬁrst to second scan
– 0.78 – 1.36
Percentage error, SPECT vs injected in phantom background (%) – 1.65 – 3.49
Note–Measurements performed by using single-photon emission CT with the same techniques used to analyze patient images are
compared versus known phantom activity concentrations.
SPECT ¼ single-photon emission computed tomography.
*Based on known decay-corrected quantities of radioactivity used to ﬁll the phantom as measured using a Biodex Atomlab 100 Dose
Calibrator.
†Performed by using identical corrections and measurement techniques as used in patient analysis.
Figure 4. Archived digital subtraction angiographic images show catheter positioning for each infusion of 99mTc MAA before
radioembolization treatment of a 73-year-old man with HCC (patient 9; Table 1): (a) antireﬂux catheter position and (b) end-hole catheter
position are shown.
Volume 26 ’ Number 5 ’ May ’ 2015 665uptake (P4 .05) when the order of infusion was varied,
ie, when MAA was infused with the antireﬂux catheter
ﬁrst and the end-hole catheter second or with the end-
hole catheter ﬁrst and the antireﬂux catheter second.
In addition to increased tumor uptake, decreased
MAA deposition in areas of normal (uninvolved) hepatic
parenchyma in the treated lobe was qualitatively identi-
ﬁed in all patients when the antireﬂux catheter was used
(Figs 2, 6a–6c). Quantitative analysis indicated that,
relative to the end-hole catheter, tumor ROI MAA
deposition in areas of normal liver with use of the
antireﬂux catheter quantitatively changed by a factor
that ranged from 0.11 to 0.76 (mean, 0.42; σ ¼ 0.19).
This relative decrease in deposition in normal liver was
statistically signiﬁcant (P o .05). These results are
summarized in Table 1.
Qualitative analysis of 90Y PET data following treat-
ment (Table 1) indicated excellent agreement betweenthe distribution of radioembolization obtained by using
the antireﬂux catheter and the distribution of MAA
by using the antireﬂux catheter. In all eight patients,
the distribution of MAA and 90Y microspheres when
the antireﬂux catheter was used closely matched
pretreatment planning intentions (Figs 5b–5d, 6b–6d).Complications
Among 17 embolizations performed by using the anti-
reﬂux catheter (nine with 99mTc MAA, eight with
resin microspheres), one infusion-related complication
occurred. During infusion of 90Y microspheres in the
third study patient, the catheter occluded as a result of
presumed clumping of microspheres and the procedure
was halted. Nuclear medicine staff determined the
percentage of the prescribed activity that was delivered
before catheter occlusion. A new radioembolization
Figure 5. In all images, arrows indicate corresponding areas of disease on each image and imaging modality. (a) Distribution of 99mTc
MAA on coronal SPECT following infusion with an end-hole catheter in a 48-year-old woman with HCC (patient 6; Table 1). (b) Coronal
SPECT demonstrates the distribution of MAA following infusion with an antireﬂux catheter. (c) Pretreatment coronal hepatic protocol
MR imaging demonstrates multicentric hepatic masses. (d) Posttreatment coronal 90Y PET/CT following infusion of radioembolic
materials with an antireﬂux catheter. Quantitative analysis showed a change in MAA deposition by a factor of 1.67 (67% increase) with
the antireﬂux catheter in the large superior mass (top arrow).
Pasciak et al ’ JVIR666 ’ Pilot Study: Antireﬂux Catheter for Liver-Directed Embolotherapytreatment dosage was prepared that matched the unde-
livered portion of the original prescription, and this
dosage was delivered on the same day by using a new
antireﬂux catheter, without further incident.DISCUSSION
In the present small patient series spanning a wide range
of treatment indications and tumor sizes, the data
suggest that the antireﬂux catheter altered the down-
stream distribution of embolic particles. In all studypatients, more uniform tumor coverage and increases in
MAA deposition in distal tumor were observed when the
antireﬂux catheter was used. Consequently, nontarget
embolization to normal liver in the treated lobe was also
decreased with the use of the antireﬂux catheter. There
are several different hypotheses describing possible
mechanisms for these effects. Based on downstream
arterial pressure measurements made with an antireﬂux
catheter tip expanded, Rose et al (15) suggested that
pressure decreases could create hepatopetal ﬂow in
downstream hepatoenteric collateral vessels, potentially
resulting in distribution changes of radioembolization
Figure 6. Arrows indicate corresponding areas on each image and imaging modality. (a) Distribution of 99mTc MAA on axial SPECT
following infusion with an end-hole catheter in a 75-year-old woman with colorectal carcinoma metastases (patient 1; Table 1). (b) Axial
SPECT demonstrates the distribution of MAA following infusion with an anti-reﬂux catheter. (c) Pretreatment axial FDG PET/CT
demonstrates peripherally hypermetabolic right-lobe hepatic mass. (d) Posttreatment axial 90Y PET/CT following infusion of
radioembolization with an antireﬂux catheter. Quantitative analysis showed a change in MAA deposition by a factor of 1.75 (75%
increase) with the antireﬂux catheter in the distal tumor in liver segment VIII (arrow). The lower arrow (segment VIII) indicates normal
liver parenchyma that showed a change in MAA deposition by a factor of 0.65 (35% decrease) with the antireﬂux catheter.
Volume 26 ’ Number 5 ’ May ’ 2015 667and other liver-directed therapies. We propose that
the results described in the present study can be
more directly explained by the hypothesis that reduction
in downstream pressure (15) with an antireﬂux micro-
catheter may result in vasoconstriction of the arteries
and arterioles supplying normal liver tissue. At the same
time, the structurally abnormal angiogenesis-induced
tumor arterioles are not likely to vasoconstrict as a
result of the absence of smooth muscle, innervation, and
autoregulatory properties (16,17). This could preferen-
tially shunt microspheres toward the tumor compart-
ment, temporarily increasing the tumor-to-normaluptake ratio. Although this hypothesis has not been
proven, it is congruent with similar ﬁndings with the use
of intraarterial infusion of angiotensin II (18) or
vasopressin (19).
The selection of infusion catheters for use in trans-
catheter liver-directed embolotherapy is largely depend-
ent on operator preference, device familiarity, and
empiric evidence. This is at least partially attributable
to the absence of standardized performance data of
catheters for the delivery of these therapies. The pre-
sented results provide evidence that a same-day, dual
99mTc MAA infusion protocol may be a valid tool to
Pasciak et al ’ JVIR668 ’ Pilot Study: Antireﬂux Catheter for Liver-Directed Embolotherapyevaluate the effect of different catheters on embolotherapy
delivery. Because this method maintains the consistency of
all variables other than the catheter, differences may be
easy to identify in a small study cohort because subjects
act as their own controls.
The validity of this technique rests on two assump-
tions, that (i) 99mTc MAA is an accurate surrogate for
90Y microspheres and (ii) the embolic effects of the ﬁrst
MAA infusion do not appreciably alter the distribution
of the second MAA infusion. Technetium 99m
MAA represents the gold standard in pretreatment
simulation of radioembolization and is a key component
of the standard-of-care lung shunt evaluation integral in
every 90Y treatment (20). It is widely suggested that
99mTc MAA may be appropriate for the performance of
pretreatment predictive dosimetry by using the partition
model (21,22), and this technique is included as part of
the 90Y Medical Internal Radiation Dose Committee
dosimetry equations (23). Posttreatment imaging with
Bremsstrahlung SPECT (24) and 90Y PET/CT (25) has
also shown good agreement with pretreatment 99mTc
MAA SPECT. In the present study, the validity of 99mTc
MAA as a 90Y microsphere surrogate was conﬁrmed by
the excellent qualitative agreement between the
posttreatment 90Y PET/CT and MAA infusions, both
performed with the antireﬂux catheter.
Although no statistically signiﬁcant differences were
identiﬁed between patient subsets based on different
MAA infusion orders, in view of the small sample size,
the possibility of a type II error cannot be ignored.
However, agreement between the distribution of 90Y
microspheres and MAA infused using an antireﬂux
catheter and imaged with 90Y PET/CT and 99mTc
MAA SPECT, respectively, suggests that the embolic
effect of the initial 40,000-particle MAA dose was
insigniﬁcant. This is because a radioembolization treat-
ment with resin microspheres can include anywhere from
8 million to 40 million microspheres in a typical dose
(26). This embolic load is much higher than any MAA
dose, but resin microspheres still mirrored the MAA
distribution in these patients when the same infusion
catheter was used.
The next step in this research is to validate these
ﬁndings in a larger patient cohort to reduce the possi-
bility of type I errors that may be present in these data.
In addition, further efforts should be performed with the
use of quantitative SPECT/CT, which would allow for a
more robust, nonsegmented approach to the analysis of
the postinfusion MAA images.ACKNOWLEDGMENT
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